MoonLake Immunotherapeutics (NASDAQ: MLTX) kicked off on Tuesday, down -3.54% from the previous trading day, before settling in for the closing price of $13.69. Over the past 52 weeks, MLTX has traded in a range of $5.95-$62.75.
Healthcare Sector giant saw their annual sales slid by -319.65% over the last five years. While this was happening, its average annual earnings per share was recorded -89.57%. With a float of $63.49 million, this company’s outstanding shares have now reached $63.70 million.
MoonLake Immunotherapeutics (MLTX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of MoonLake Immunotherapeutics is 10.39%, while institutional ownership is 60.63%. The most recent insider transaction that took place on Dec 08 ’25, was worth 1,960,400. In this transaction Chief Executive Officer of this company sold 130,000 shares at a rate of $15.08, taking the stock ownership to the 2,948,577 shares. Before that another transaction happened on Dec 09 ’25, when Company’s Chief Executive Officer sold 70,000 for $14.49, making the entire transaction worth $1,014,300. This insider now owns 2,878,577 shares in total.
MoonLake Immunotherapeutics (MLTX) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.72 earnings per share (EPS), lower than consensus estimate (set at -0.59) by -0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -89.57% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -21.75% during the next five years compared to -319.65% drop over the previous five years of trading.
MoonLake Immunotherapeutics (NASDAQ: MLTX) Trading Performance Indicators
Take a look at MoonLake Immunotherapeutics’s (MLTX) current performance indicators. Last quarter, stock had a quick ratio of 8.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.33, a number that is poised to hit -0.99 in the next quarter and is forecasted to reach -3.62 in one year’s time.
Technical Analysis of MoonLake Immunotherapeutics (MLTX)
Analysing the last 5-days average volume posted by the [MoonLake Immunotherapeutics, MLTX], we can find that recorded value of 0.87 million was lower than the volume posted last year of 1.73 million. As of the previous 9 days, the stock’s Stochastic %D was 21.14%.
During the past 100 days, MoonLake Immunotherapeutics’s (MLTX) raw stochastic average was set at 12.78%, which indicates a significant increase from 5.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.71 in the past 14 days, which was lower than the 1.40 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.46, while its 200-day Moving Average is $35.20. Now, the first resistance to watch is $13.52. This is followed by the second major resistance level at $13.84. The third major resistance level sits at $13.99. If the price goes on to break the first support level at $13.05, it is likely to go to the next support level at $12.90. Now, if the price goes above the second support level, the third support stands at $12.58.
MoonLake Immunotherapeutics (NASDAQ: MLTX) Key Stats
The company with the Market Capitalisation of 942.84 million has total of 64,231K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -118,940 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -69,730 K.
